Showing 1-10 of 106 results for "".
Board Forum: Inclusive Practice
https://modernaesthetics.com/ma-issues-index/2020-jan-feb/board-forum-inclusive-practice/34863/- January/February 2020 Insert - MA Supplementshttps://modernaesthetics.com/ma-supplements/2020-jan-feb-insert/
MEETING NOTES
https://modernaesthetics.com/ma-issues-index/2014-sept-oct/meeting-notes/34595/News from recent meetings, and a guide to upcoming events.- Update: Revance Starts Phase III Studies on RT002 for Frown Lineshttps://modernaesthetics.com/news/revance-starts-phase-iii-studies-on-rt002-for-frown-lines/2472297/Revance Therapeutics began two double-blind, placebo-controlled, North American Phase III trials to evaluate single injections of DaxibotulinumtoxinA (RT002) for the treatment glabellar lines in about 600 total patients. These pivotal trials
- Lizette Williams, Global Head of Vertical Solutions Marketing at Facebook, Joins RealSelf’s Boardhttps://modernaesthetics.com/news/lizette-williams-global-head-of-vertical-solutions-marketing-at-facebook-joins-realselfs-board-1/2472996/Marketing and advertising executive Lizette Williams is the newest member of RealSelf’s Board of Directors. Ms. Williams serves as the Global Head of Vertical Solutions Marketing at Facebook. Prior to Facebook she has worked in major marketing roles at McDonald's, Kimberl
- Evolus Launches “Drop the F Word” Campaign Ahead of Evolysse Injectable HA Gelshttps://modernaesthetics.com/news/evolus-launches-drop-the-f-word-campaign-ahead-of-evolysse-injectable-ha-gels/2475348/Evolus, Inc. rolled out a new campaign, “Drop the F Word,” ahead of the upcoming commercial launch of EvolysseTM injectable hyaluronic acid gels. The campaign aims to challenge outdated perceptions and language in the aesthetics industry, according to a press release, and introduces Ev
- GALDA Co-Director Explains Organization's Work and Impacthttps://modernaesthetics.com/news/galda-co-director-explains-organizations-work-and-impact/2475382/The Gay and Lesbian Dermatology Association (GALDA) is an organization of dermatologists and health-care professionals dedicated to unity and networking of the gay community at dermatology meetings. For Pride Month, we spoke with GALDA co-director William L Waller III, MD, FAAD, to learn more abo
- GPX4 Modulator Shows Early Promise in First-in-Human Studyhttps://modernaesthetics.com/news/gpx4-modulator-shows-early-promise-in-first-in-human-study/2486474/A novel topical therapy targeting cellular senescence showed early biologic activity across multiple dermatologic conditions in a Phase 1 clinical trial, according to data presented by Frederick Beddingfield III, MD, PhD, FAAD, at the Dermatology Innovation Forum during the American Academy of De
- Tattoo Removal Trends Revealed in Global Analysis of Over 200,000 Individualshttps://modernaesthetics.com/news/tattoo-removal-trends-revealed-in-global-analysis-of-over-200000-individuals/2475357/Key Takeaways Individuals aged 18–39 make up two-thirds of those seeking tattoo removal, with visible areas such as forearms and hands being the most treated. Black ink remains the most commonly removed tattoo pigment. Fitzpatrick Skin Types III and
- New Data Demonstrates Long-Term Safety, Efficacy of Galderma’s RelabotulinumtoxinAhttps://modernaesthetics.com/news/new-data-demonstrates-long-term-safety-efficacy-of-galdermas-relabotulinumtoxina/2473698/Galderma presented new phase III data from the READY-4 clinical trial at the American Society for Dermatologic Surgery (ASDS) 2024 Annual Meeting last week. The data demonstrates the long-term safety of RelabotulinumtoxinA (RelfydessTM) for frown lines and crow’s feet after repea
- Prev
- Next